Purpose <p>To determine if the developed <i>Know Your Risk</i> (KYR) intervention is similar to conventional genetic counseling; we evaluated participants’ knowledge of cancer genetics, breast cancer risk perception, attitudes about genetic counseling and testing, and satisfaction with genetic counseling.</p> Methods <p>Women (<i>n</i> = 866) who screened at elevated risk for breast cancer were randomized to the KYR intervention or conventional genetic counseling (2022–2024). The KYR intervention included a series of online pre-test educational videos, direct access to genetic testing, and patient preference for receiving post-test genetic counseling. Participants completed surveys at baseline and after genetic counseling and testing. Non-inferiority hypothesis testing compared the two participant groups.</p> Results <p>The mean knowledge score (range 0–12) increased in both study groups from a baseline mean of 6.87 (standard deviation (SD) = 2.46) to 8.66 (SD = 2.16) for the KYR intervention and 8.56 (SD = 2.14) for conventional counseling. Additionally, statistical analyses suggest the non-inferiority of the KYR intervention for participants’ accuracy of their breast cancer risk, attitudes about genetic counseling and genetic testing, and satisfaction with genetic counseling compared to participants randomized to conventional genetic counseling.</p> Conclusion <p>Findings support that the components included in the KYR intervention are non-inferior for cancer genetic knowledge, risk perception, genetic counseling and testing attitudes, and genetic counseling satisfaction among women who screen at elevated risk for breast cancer. By using the combination of components included in the KYR intervention, genetic counseling and genetic testing are more accessible, convenient, and patient-driven.</p> <p><i>Trial Registration</i>: ClinicalTrials.gov Identifier: NCT05325151.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Knowledge of cancer genetics and attitudes about genetic counseling and testing: a randomized trial of the Know Your Risk intervention compared to conventional genetic counseling

  • Mira L. Katz,
  • Patrick M. Schnell,
  • Paul L. Reiter,
  • Leigha Senter,
  • Amber Aeilts,
  • Christina Spears,
  • Julia Cooper,
  • Jordan Brown,
  • Kate P. Shane-Carson,
  • Doreen M. Agnese,
  • Amanda E. Toland,
  • Kevin Sweet

摘要

Purpose

To determine if the developed Know Your Risk (KYR) intervention is similar to conventional genetic counseling; we evaluated participants’ knowledge of cancer genetics, breast cancer risk perception, attitudes about genetic counseling and testing, and satisfaction with genetic counseling.

Methods

Women (n = 866) who screened at elevated risk for breast cancer were randomized to the KYR intervention or conventional genetic counseling (2022–2024). The KYR intervention included a series of online pre-test educational videos, direct access to genetic testing, and patient preference for receiving post-test genetic counseling. Participants completed surveys at baseline and after genetic counseling and testing. Non-inferiority hypothesis testing compared the two participant groups.

Results

The mean knowledge score (range 0–12) increased in both study groups from a baseline mean of 6.87 (standard deviation (SD) = 2.46) to 8.66 (SD = 2.16) for the KYR intervention and 8.56 (SD = 2.14) for conventional counseling. Additionally, statistical analyses suggest the non-inferiority of the KYR intervention for participants’ accuracy of their breast cancer risk, attitudes about genetic counseling and genetic testing, and satisfaction with genetic counseling compared to participants randomized to conventional genetic counseling.

Conclusion

Findings support that the components included in the KYR intervention are non-inferior for cancer genetic knowledge, risk perception, genetic counseling and testing attitudes, and genetic counseling satisfaction among women who screen at elevated risk for breast cancer. By using the combination of components included in the KYR intervention, genetic counseling and genetic testing are more accessible, convenient, and patient-driven.

Trial Registration: ClinicalTrials.gov Identifier: NCT05325151.